Tag: Alvotech

FDA, Regulations

Stelara biosimilar from Alvotech, Teva approved by FDA

April 17, 2024

Via: Biopharma Dive

Stelara is one of many top-selling medicines that will face competition from copycat versions this decade, including a large number of biologic drugs. AbbVie’s anti-inflammatory medicine Humira — sales of which topped $21 billion in 2022 — has been a […]

FDA, Regulations

FDA approves Alvotech and Teva’s Simlandi as interchangeable Humira biosimilar

February 26, 2024


Simlandi has been approved by the regulator to treat rheumatoid arthritis, idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa and uveitis. Biosimilars, according to the FDA, are biological products that are highly similar to […]

Industry, News, Pharma

Teva Pharmaceuticals, Alvotech Expand Strategic Biosimilars Pact

July 25, 2023

Via: Contract Pharma

Teva Pharmaceuticals, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd., and Alvotech, a global biotech company specializing in the development and manufacture of biosimilars, expanded their existing strategic partnership agreement. Teva will also acquire subordinated convertible bonds to be […]